Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.

Clunas, S, et al. (2010) 3,6-Disubstituted xanthylium salts. Patent.

Wischik, C.M., et al. (2010) Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC): methods of treatment of a tauopathy condition comprising the use of thioninium compounds. Patent

Wischik, C.M., et al. (2010) Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. In Emerging drugs and targets for Alzheimer's disease. Available at: RSC Drug Discovery Series